Status:
TERMINATED
Gemcitabine for Marginal Zone Lymphoma
Lead Sponsor:
Asan Medical Center
Collaborating Sponsors:
Eli Lilly and Company
Conditions:
Non-Hodgkin's Lymphoma
Marginal Zone Lymphoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Marginal zone lymphoma, one of the indolent lymphoma, is believed to be incurable with chemotherapy. Thus the investigators need a novel agent for marginal zone lymphoma. Gemcitabine has been tried as...
Detailed Description
We designed a multi-center phase II trial of gemcitabine for advanced stage marginal zone B-cell lymphoma. Marginal zone lymphoma needs novel agent to improve clinical course by chemotherapy. Recent t...
Eligibility Criteria
Inclusion
- Histologically confirmed marginal zone B-cell lymphoma
- Performance status (ECOG) ≤3
- Age ≥ 18
- At least one or more bidimensionally measurable lesion(s):
- 2 cm by conventional CT
- 1 cm by spiral CT
- skin lesion (photographs should be taken)
- measurable lesion by physical examination
- Laboratory values:
- Cr \< 2.0 mg% or Ccr \> 60 ml/min
- Transaminase \< 3 X upper normal value
- Bilirubin \< 2 mg%
- ANC \> 1500/ul, platelet \> 75,000/ul
- Informed consent
- Ann Arbor stage III or IV
Exclusion
- Any other malignancies within the past 5 years except skin basal cell ca or CIS of cervix
- Serious comorbid diseases
- Pregnancy or breast feeding
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2009
Estimated Enrollment :
43 Patients enrolled
Trial Details
Trial ID
NCT00337259
Start Date
June 1 2006
End Date
March 1 2009
Last Update
February 17 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Asan Medical Center
Seoul, South Korea, 138-736